Omeros Corporation is positioned to dominate the TM-TMA market with Yartemlea, the only FDA-approved therapy for this indication. See why I rate OMER stock a hold.
Cantor upgrades Omeros to Overweight with a $22 price forecast following strong Yartemlea sales and Medicare reimbursement momentum.
Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.
Arnold C Hanish, Director, on August 26, 2026, sold 15,000 shares in Omeros (OMER) for $282,094. Fol
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Thomas J. Cable, Director, on August 20, 2026, sold 15,000 shares in Omeros (OMER) for $276,773. Fol
This is the newest page. Registered accounts read further back.